Earnings Call Summary | Zoetis(ZTS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Zoetis(ZTS.US) Q1 2024 Earnings Conference
The following is a summary of the Zoetis Inc (ZTS) Q1 2024 Earnings Call Transcript:
以下是佐蒂斯公司（ZTS）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Zoetis reported Q1 revenue of $2.2 billion, growing 10% from the same period last year, with $1.2 billion from the U.S. (16% increase) and $1 billion internationally (8% increase).
The adjusted net income amounted to $634 million, a 4% increase.
The company has raised its 2024 operational guidance, expecting yearly revenue between $9.05 billion and $9.20 billion (8.5 to 10.5% operational growth).
The forecast for the full-year adjusted net income ranges between $2.62 billion to $2.67 billion and the adjusted diluted EPS is expected to land between $5.71 to $5.81.
Zoetis報告稱，第一季度收入爲22億美元，比去年同期增長10％，其中12億美元來自美國（增長16％），10億美元來自國際（增長8％）。
調整後的淨收入爲6.34億美元，增長4％。
該公司提高了其2024年的運營指導，預計年收入在90.5億美元至92.0億美元之間（運營增長8.5％至10.5％）。
全年調整後淨收益的預測在26.2億美元至26.7億美元之間，調整後的攤薄每股收益預計將在5.71美元至5.81美元之間。
Business Progress:
業務進展：
Zoetis' OA pain mAbs Librela and Solensia are showing positive growth with strong reorder rates of 80%.
The launch of Apoquel chewable has resulted in solid conversions.
Despite an operational decline of 12% in Zoetis' companion animal diagnostics portfolio, influenced by a distribution model change, and the economic challenges faced by the livestock business in China, the company has still increased its operational guidance for 2024.
The company has entered into an agreement with Phibro Animal Health which aligns with its strategic growth plans.
Major product launches are planned while maintaining a dedicated focus on livestock innovations in the areas of preventatives, antibiotic alternatives, and genetics.
Zoetis plans to sell off its global medicated feed additives and certain water-soluble product portfolios to redirect focus and investments.
The company reports growth across key therapeutic areas and major markets, with expectations of future growth due to the diversity and reliability of those growth capabilities.
Zoetis maintains a strong R&D pipeline across key therapeutic areas, underscoring its relevancy in the market.
The company strives to create new markets and launch innovative products that elevate the standard of medical care for animals.
Zoetis的OA止痛藥Librela和Solensia表現出正增長，強勁的再訂購率爲80％。
Apoquel Chewable的推出帶來了可觀的轉化率。
儘管受分銷模式變化以及中國畜牧業務面臨的經濟挑戰的影響，Zoetis的伴侶動物診斷產品組合的運營下降了12％，但該公司仍提高了2024年的運營指導。
該公司已與Phibro Animal Health簽訂了一項協議，該協議符合其戰略增長計劃。
計劃推出主要產品，同時繼續專注於預防劑、抗生素替代品和遺傳學領域的牲畜創新。
Zoetis計劃出售其全球藥用飼料添加劑和某些水溶性產品組合，以重新調整重點和投資。
該公司報告了關鍵治療領域和主要市場的增長，由於這些增長能力的多樣性和可靠性，預計未來將實現增長。
Zoetis在關鍵治療領域保持着強大的研發渠道，這凸顯了其在市場中的重要性。
該公司致力於創造新市場並推出創新產品，以提高動物醫療保健的標準。
More details: Zoetis IR
更多詳情： Zoetis IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。